ChemoCentryx Initiates a Phase II Clinical Trial For CCX140 A Novel Inhibitor of the Chemokine Receptor CCR2 for the Treatment of Diabetic Nephropathy

&160; MOUNTAIN VIEW Calif. Dec. 8 2011 PRNewswire ChemoCentryx Inc. today announced the initiation of a Phase II clinical trial for CCX140 an orallyadministered small molecule for the treatment of diabetic kidney disease diabetic nephropathy.&160...